{"title":"托莱多(西班牙),2021年12月至2022年2月期间,接种普通医学疫苗加强针的人群中新冠肺炎突破性感染的风险因素和发病率","authors":"Turabian Jose Luis","doi":"10.17352/2455-5479.000179","DOIUrl":null,"url":null,"abstract":"Background: The effectiveness of vaccines against COVID-19 has been demonstrated, but because new variants appear and immunity fades over time, continuous monitoring is necessary. Objectives: To determine incidence rates (IR) and risk factors of COVID-19 breakthrough infections in vaccinated people with vaccine booster (VB). Methodology: An observational, longitudinal, and prospective study of patients with COVID-19 breakthrough infections in vaccinated people with VB in a general practice setting in Toledo, Spain, for the period December 2021 to February 2022, during the wave of infections by omicron variant. Results: Forty-six cases of COVID-19 breakthrough infections with booster shot were included. The IR was 3.1 cases per 100 people with booster. The IR was higher in < 45 years (4.7%) vs. > 65 years (4.2%), and in women (3.6%) vs. man (2.6%). The only statistically significant risk/prevention factors were the presence of diseases of the skin [RR = 2.74 (95% CI: 1.3, 5.79)], Genitourinary chronic diseases [RR = 1.87 (95% CI: 1.19, 2.95)], complex family [RR = 0.22 (CI 95%: 0.58, 0.08)] and chronic diseases of the mental group [RR = 0.4 (95% CI: 0.82, 0.2)]. Conclusion: The IR of COVID-19 breakthrough infections with a booster shot, at the peak of omicron infections (December 2021-February 2022), in the general medicine clinic, Toledo, Spain, was high, suggesting modest VB protection effectiveness against symptomatic infection. Statistically significant risk and protective factors show mixed results; so, it is hypothesized that they are related to other main variables such as gender and age, and/or with risk/preventive behaviors. However, the small numbers of COVID-19 breakthrough infections with booster shots prevent definitive conclusions.","PeriodicalId":87221,"journal":{"name":"Archives of community medicine and public health","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk factors and incidence rates of COVID-19 breakthrough infections in vaccinated people with vaccine booster in general medicine, Toledo (Spain), for the period December 2021 to February 2022\",\"authors\":\"Turabian Jose Luis\",\"doi\":\"10.17352/2455-5479.000179\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: The effectiveness of vaccines against COVID-19 has been demonstrated, but because new variants appear and immunity fades over time, continuous monitoring is necessary. Objectives: To determine incidence rates (IR) and risk factors of COVID-19 breakthrough infections in vaccinated people with vaccine booster (VB). Methodology: An observational, longitudinal, and prospective study of patients with COVID-19 breakthrough infections in vaccinated people with VB in a general practice setting in Toledo, Spain, for the period December 2021 to February 2022, during the wave of infections by omicron variant. Results: Forty-six cases of COVID-19 breakthrough infections with booster shot were included. The IR was 3.1 cases per 100 people with booster. The IR was higher in < 45 years (4.7%) vs. > 65 years (4.2%), and in women (3.6%) vs. man (2.6%). The only statistically significant risk/prevention factors were the presence of diseases of the skin [RR = 2.74 (95% CI: 1.3, 5.79)], Genitourinary chronic diseases [RR = 1.87 (95% CI: 1.19, 2.95)], complex family [RR = 0.22 (CI 95%: 0.58, 0.08)] and chronic diseases of the mental group [RR = 0.4 (95% CI: 0.82, 0.2)]. Conclusion: The IR of COVID-19 breakthrough infections with a booster shot, at the peak of omicron infections (December 2021-February 2022), in the general medicine clinic, Toledo, Spain, was high, suggesting modest VB protection effectiveness against symptomatic infection. Statistically significant risk and protective factors show mixed results; so, it is hypothesized that they are related to other main variables such as gender and age, and/or with risk/preventive behaviors. However, the small numbers of COVID-19 breakthrough infections with booster shots prevent definitive conclusions.\",\"PeriodicalId\":87221,\"journal\":{\"name\":\"Archives of community medicine and public health\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of community medicine and public health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17352/2455-5479.000179\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of community medicine and public health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17352/2455-5479.000179","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Risk factors and incidence rates of COVID-19 breakthrough infections in vaccinated people with vaccine booster in general medicine, Toledo (Spain), for the period December 2021 to February 2022
Background: The effectiveness of vaccines against COVID-19 has been demonstrated, but because new variants appear and immunity fades over time, continuous monitoring is necessary. Objectives: To determine incidence rates (IR) and risk factors of COVID-19 breakthrough infections in vaccinated people with vaccine booster (VB). Methodology: An observational, longitudinal, and prospective study of patients with COVID-19 breakthrough infections in vaccinated people with VB in a general practice setting in Toledo, Spain, for the period December 2021 to February 2022, during the wave of infections by omicron variant. Results: Forty-six cases of COVID-19 breakthrough infections with booster shot were included. The IR was 3.1 cases per 100 people with booster. The IR was higher in < 45 years (4.7%) vs. > 65 years (4.2%), and in women (3.6%) vs. man (2.6%). The only statistically significant risk/prevention factors were the presence of diseases of the skin [RR = 2.74 (95% CI: 1.3, 5.79)], Genitourinary chronic diseases [RR = 1.87 (95% CI: 1.19, 2.95)], complex family [RR = 0.22 (CI 95%: 0.58, 0.08)] and chronic diseases of the mental group [RR = 0.4 (95% CI: 0.82, 0.2)]. Conclusion: The IR of COVID-19 breakthrough infections with a booster shot, at the peak of omicron infections (December 2021-February 2022), in the general medicine clinic, Toledo, Spain, was high, suggesting modest VB protection effectiveness against symptomatic infection. Statistically significant risk and protective factors show mixed results; so, it is hypothesized that they are related to other main variables such as gender and age, and/or with risk/preventive behaviors. However, the small numbers of COVID-19 breakthrough infections with booster shots prevent definitive conclusions.